These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 22213451)
1. Interaction of the non-phosphorylated peptide G7-18NATE with Grb7-SH2 domain requires phosphate for enhanced affinity and specificity. Gunzburg MJ; Ambaye ND; Del Borgo MP; Pero SC; Krag DN; Wilce MC; Wilce JA J Mol Recognit; 2012 Jan; 25(1):57-67. PubMed ID: 22213451 [TBL] [Abstract][Full Text] [Related]
2. Structural basis of binding by cyclic nonphosphorylated peptide antagonists of Grb7 implicated in breast cancer progression. Ambaye ND; Pero SC; Gunzburg MJ; Yap M; Clayton DJ; Del Borgo MP; Perlmutter P; Aguilar MI; Shukla GS; Peletskaya E; Cookson MM; Krag DN; Wilce MC; Wilce JA J Mol Biol; 2011 Sep; 412(3):397-411. PubMed ID: 21802427 [TBL] [Abstract][Full Text] [Related]
3. Uptake of a cell permeable G7-18NATE contruct into cells and binding with the Grb-7-SH2 domain. Ambaye ND; Lim RC; Clayton DJ; Gunzburg MJ; Price JT; Pero SC; Krag DN; Wilce MC; Aguilar MI; Perlmutter P; Wilce JA Biopolymers; 2011; 96(2):181-8. PubMed ID: 20564009 [TBL] [Abstract][Full Text] [Related]
4. Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation. Porter CJ; Matthews JM; Mackay JP; Pursglove SE; Schmidberger JW; Leedman PJ; Pero SC; Krag DN; Wilce MC; Wilce JA BMC Struct Biol; 2007 Sep; 7():58. PubMed ID: 17894853 [TBL] [Abstract][Full Text] [Related]
5. NMR analysis of G7-18NATE, a nonphosphorylated cyclic peptide inhibitor of the Grb7 adapter protein. Porter CJ; Wilce JA Biopolymers; 2007; 88(2):174-81. PubMed ID: 17206629 [TBL] [Abstract][Full Text] [Related]
6. Cyclic Peptides Incorporating Phosphotyrosine Mimetics as Potent and Specific Inhibitors of the Grb7 Breast Cancer Target. Watson GM; Gunzburg MJ; Ambaye ND; Lucas WA; Traore DA; Kulkarni K; Cergol KM; Payne RJ; Panjikar S; Pero SC; Perlmutter P; Wilce MC; Wilce JA J Med Chem; 2015 Oct; 58(19):7707-18. PubMed ID: 26359549 [TBL] [Abstract][Full Text] [Related]
7. Preparation and crystallization of the Grb7 SH2 domain in complex with the G7-18NATE nonphosphorylated cyclic inhibitor peptide. Yap MY; Wilce MC; Clayton DJ; Perlmutter P; Aguilar MI; Wilce JA Acta Crystallogr Sect F Struct Biol Cryst Commun; 2010 Dec; 66(Pt 12):1640-3. PubMed ID: 21139214 [TBL] [Abstract][Full Text] [Related]
8. Insight into the Selectivity of the G7-18NATE Inhibitor Peptide for the Grb7-SH2 Domain Target. Watson GM; Lucas WAH; Gunzburg MJ; Wilce JA Front Mol Biosci; 2017; 4():64. PubMed ID: 29018805 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cyclic Peptide Inhibitors of the Grb7 Breast Cancer Target: Small Change in Cargo Results in Large Change in Cellular Activity. Sang J; Kulkarni K; Watson GM; Ma X; Craik DJ; Henriques ST; Poth AG; Benfield AH; Wilce JA Molecules; 2019 Oct; 24(20):. PubMed ID: 31627265 [TBL] [Abstract][Full Text] [Related]
10. Unexpected involvement of staple leads to redesign of selective bicyclic peptide inhibitor of Grb7. Gunzburg MJ; Kulkarni K; Watson GM; Ambaye ND; Del Borgo MP; Brandt R; Pero SC; Perlmutter P; Wilce MC; Wilce JA Sci Rep; 2016 Jun; 6():27060. PubMed ID: 27257138 [TBL] [Abstract][Full Text] [Related]
11. Solution structure of the human Grb14-SH2 domain and comparison with the structures of the human Grb7-SH2/erbB2 peptide complex and human Grb10-SH2 domain. Scharf PJ; Witney J; Daly R; Lyons BA Protein Sci; 2004 Sep; 13(9):2541-6. PubMed ID: 15322292 [TBL] [Abstract][Full Text] [Related]
12. Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells. Pero SC; Shukla GS; Cookson MM; Flemer S; Krag DN Br J Cancer; 2007 May; 96(10):1520-5. PubMed ID: 17426702 [TBL] [Abstract][Full Text] [Related]
13. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. Tanaka S; Pero SC; Taguchi K; Shimada M; Mori M; Krag DN; Arii S J Natl Cancer Inst; 2006 Apr; 98(7):491-8. PubMed ID: 16595785 [TBL] [Abstract][Full Text] [Related]
14. Discovery, Development, and Cellular Delivery of Potent and Selective Bicyclic Peptide Inhibitors of Grb7 Cancer Target. Watson GM; Kulkarni K; Sang J; Ma X; Gunzburg MJ; Perlmutter P; Wilce MCJ; Wilce JA J Med Chem; 2017 Nov; 60(22):9349-9359. PubMed ID: 29083893 [TBL] [Abstract][Full Text] [Related]
15. Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7. Pero SC; Oligino L; Daly RJ; Soden AL; Liu C; Roller PP; Li P; Krag DN J Biol Chem; 2002 Apr; 277(14):11918-26. PubMed ID: 11809769 [TBL] [Abstract][Full Text] [Related]
16. Development of binding assays for the SH2 domain of Grb7 and Grb2 using fluorescence polarization. Luzy JP; Chen H; Gril B; Liu WQ; Vidal M; Perdereau D; Burnol AF; Garbay C J Biomol Screen; 2008 Feb; 13(2):112-9. PubMed ID: 18216394 [TBL] [Abstract][Full Text] [Related]
17. Preparation of crystals for characterizing the Grb7 SH2 domain before and after complex formation with a bicyclic peptide antagonist. Ambaye ND; Gunzburg MJ; Traore DA; Del Borgo MP; Perlmutter P; Wilce MC; Wilce JA Acta Crystallogr F Struct Biol Commun; 2014 Feb; 70(Pt 2):182-6. PubMed ID: 24637751 [TBL] [Abstract][Full Text] [Related]
18. Structural basis for dimerization of the Grb10 Src homology 2 domain. Implications for ligand specificity. Stein EG; Ghirlando R; Hubbard SR J Biol Chem; 2003 Apr; 278(15):13257-64. PubMed ID: 12551896 [TBL] [Abstract][Full Text] [Related]
19. Design and testing of bicyclic inhibitors of Grb7--are two cycles better than one? Gunzburg MJ; Ambaye ND; Del Borgo MP; Perlmutter P; Wilce JA Biopolymers; 2013 Sep; 100(5):543-9. PubMed ID: 23505041 [TBL] [Abstract][Full Text] [Related]
20. Progress towards the development of SH2 domain inhibitors. Kraskouskaya D; Duodu E; Arpin CC; Gunning PT Chem Soc Rev; 2013 Apr; 42(8):3337-70. PubMed ID: 23396540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]